This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Advances such as tablet technology and cloud computing mean that a fully commercial product to reliably regulate insulin might be within reach.
Aptitude creates a special type of molecule called an aptamer, which it is using to develop a first-of-its-kind hand-held device that measures insulin concentrations in real-time and can diagnose pre-diabetes. The government’s interest in furthering such research is unsurprising as diabetes affects more than 9 percent of Americans.
In May 1922, Dr. William Sansum injected a diabetes patient with insulin for the first time in the U.S., instantly increasing life expectancy from mere weeks to many years. His patient lived to 90.
With $2.3 million in recent federal funding, Sansum Diabetes Research Institute is moving forward with clinical trials of its artificial pancreas, a device that researchers hope will substantially improve the lives of people living with Type 1 diabetes.
A device made by Santa Barbara-based Active Life Scientific played a critical role in a new study at the Mayo Clinic linking Type 2 diabetes to bone problems.
New research conducted on the South Coast could point the way to the prevention and cure of type two diabetes.